DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Information source: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV

Intervention: Lopinavir (Drug); Atazanavir (Drug)

Phase: Phase 3

Status: Withdrawn

Sponsored by: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Official(s) and/or principal investigator(s):
Eric Delaporte, Principal Investigator, Affiliation: Institut de Recherche pour le Developpement, France
Issakwisa Mwakyula, Principal Investigator, Affiliation: NIMR-Mbeya Medical Research Program-Mbeya Referral Hospital, Tanzania
Mzileni O Mogiyana, Principal Investigator, Affiliation: University of Limpopo
Alexandra Calmy, Principal Investigator, Affiliation: University of Geneva, Switzerland

Summary

In the well recognized context of HIV infection chronicity, it is now crucial to identify and evaluate effective, well tolerated and affordable second line regimen in resources limited countries where patients often change treatment after a long period of viral replication while on first line regimen. This multicentre international, randomized, non-blinded phase III trial aim to demonstrate the non-inferiority of a generic lamivudine-tenofovir-atazanavir/ritonavir regimen (daily intake) as compared to a standard emtricitabine-tenofovir-lopinavir/ritonavir (twice daily intake)regimen for second line HIV-1 treatment. by stratifying on the viral load level (between 1000 and 5000 copies/mL versus > 5000 copies/mL) at inclusion, this trial will also allow to evaluate the optimum moment for instituting the second-line treatment.

Clinical Details

Official title: A Multicenter Phase III Trial of Second-line Antiretroviral Treatment Strategies in African Adults (Tanzania Ans South Africa) Using Atazanavir or Lopinavir/Ritonavir

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Virological response

Secondary outcome:

Virological response

Viral resistance

Clinical course of HIV infection

Tolerance assessment

Adherence assessment

Hepatitis B evaluation

Immunologic response

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- age 18 and above

- out patient

- documented HIV-1 infection

- first line treatment failure:

- after first-line antiretroviral treatment with a combination including a

non-nucleoside reverse transcriptase inhibitor and two nucleoside reverse transcriptase inhibitors

- two measurements of plasma HIV RNA levels > 1000 copies/mL after at least 6

months of uninterrupted treatment or without any major modification

- satisfactory compliance (>80%) to 1st line antiretroviral treatment

- signed informed consent

- agreement for contraception for women of childbearing age

Exclusion Criteria:

- HIV-2 infection or HIV-1/HIV-2 coinfection

- uncontrolled, ongoing opportunistic infection or of any severe or progressive disease

including active TB

- first line antiretroviral treatment with a protease inhibitor or tenofovir

- ongoing treatment with rifampicin

- severe hepatic insufficiency (PT < 50%)

- ALT < 3 times the upper limit of normal

- creatinine clearance calculated by Cockcroft's formula < 50 mL/min

- Hb <=8 g/dL; platelets < 50,000 cells/mm3; neutrophils < 500 cells/mm3

- pregnancy and lactation

Locations and Contacts

Tshepang clinic, Limpopo University, Pretoria, South Africa

NIMR-Mbeya Medical Research Program-Mbeya Referral Hospital, Mbeya, Tanzania

Additional Information

Starting date: March 2012
Last updated: November 7, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017